<DOC>
	<DOCNO>NCT00430521</DOCNO>
	<brief_summary>The aim study ass safety &amp; immunogenicity pandemic influenza vaccine administer 2 different time point . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>Safety &amp; Immunogenicity Alternative Immunization Schedule GSK Bio 's Pandemic Influenza Vaccine ( GSK1119711A )</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol enrol study . A male female , include , 18 60 year age time first vaccination . Written inform consent obtain subject . Healthy subject establish medical history clinical examination enter study . If subject female , must nonchildbearing potential ; , childbearing potential , must abstinent use adequate contraceptive precaution 30 day prior first vaccination , negative pregnancy test must agree continue precaution two month completion vaccination series . Administration license vaccine within 2 week ( inactivated vaccine ) 4 week ( live vaccine ) prior enrolment study . History vaccination investigational influenza pandemic vaccine . History administration experimental/licensed vaccine Planned administration vaccine foreseen study protocol follow period : Day 0 Day 51 ; 2 week ( inactivated vaccine ) 4 week ( live vaccine ) prior Month 6 Month 12 ; Month 6 Month 6 + 30 day ; Month 12 Month 12 + 30 day . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior first administration candidate vaccine Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination History hypersensitivity vaccine . History allergic disease reaction likely exacerbate component vaccine . History chronic alcohol consumption and/or drug abuse . Acute clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine physical examination laboratory screen test . Serious chronic disease include medically significant chronic pulmonary , cardiovascular , renal , neurological , psychiatric metabolic disorder , determine medical history physical examination . Acute disease time enrolment . Administration immunoglobulins and/or blood product within three month precede first administration candidate vaccine study . Lactating woman . Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day prior first vaccination , plan use study period . Any condition , opinion investigator , prevents subject participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Pandemic Flu</keyword>
	<keyword>Pandemic influenza vaccine ( GSK1119711A )</keyword>
</DOC>